Bacteraemic pneumococcal pneumonia: Current therapeutic options

Drugs

Volumn 71, Issue 2, 2011, Pages 131-153

  Feldman, Charles ^a   Anderson, Ronald ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Beta lactams, therapeutic use; Community acquired pneumonia, treatment; Corticosteroids, therapeutic use; Fluoroquinolones, therapeutic use; Macrolides, therapeutic use; Penicillins, therapeutic use; Pneumococcal infections, diagnosis; Pneumococcal infections, epidemiology; Pneumococcal infections, treatment; Tetracyclines, therapeutic use.

Indexed keywords

ADHESIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLINDAMYCIN; CORTICOSTEROID; GEMIFLOXACIN; HYALURONIDASE; HYDROGEN PEROXIDE; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PENICILLIN V; PNEUMOLYSIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THROMBOCYTE ACTIVATING FACTOR; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; LIFESTYLE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SMOKING HABIT; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 79551526450     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585310-000000000-00000     Document Type: Article

References (162)

1. Varon E, Mainardi JL, Gutmann L. Streptococcus pneu-moniae: still a major pathogen. Clin Microbiol Infect 2010; 16 (5): 401
2. Feldman C, Anderson R. New insights into pneumococcal disease. Respirology 2009; 14: 167-79
3. van der Poll T, Opal SM. Pathogenesis, treatment and preven-tion of pneumococcal pneumonia. Lancet 2009; 374: 1543-56
4. Herrero FS, Perez TL, Olivas JB. Bacteremic Streptococcus pneumoniae in community-acquired pneumonia: an update. Curr Resp Med Rev 2010; 6: 188-93
5. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000; 342: 681-9
6. Jover F, Cuadrado JM, Andreu L, et al. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med 2008; 19 (1): 15-21
7. Calbo E, Valdes E, Ochoa de Echaguen A, et al. Bacter- aemic pneumococcal pneumonia in COPD patients: better outcomes than expected. Eur J Clin Microbiol Infect Dis 2009; 28: 971-6
8. Kourtis AP, Ellington S, Bansil P, et al. Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine. J Acquir Immune Defic Syndr 2010; 55 (1): 128-31
9. Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 2000; 15: 638-46
10. Feldman C, Klugman KP, Yu VL, et al. Bacteraemic pneu- mococcal pneumonia: impact of HIV on clinical presentation and outcome. J Infect 2007; 55: 125-35
11. Perello R, Miro O, Marcos MA, et al. Predicting bactere-mic pneumonia in HIV-1-infected patients consulting the ED. Am J Emerg Med 2010; 28: 454-9
12. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-7
13. Balakrishnan I, Crook P, Morris R, et al. Early predictors of mortality in pneumococcal bacteraemia. J Infect 2000; 40 (3): 256-61
14. De Graeve D, Beutels P. Economic aspects of pneumo-coccal pneumonia: a review of the literature. Pharmaco-economics 2004; 22 (11): 719-40
15. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144-54
16. Mitchell TJ, Andrew PW. Biological properties of pneu-molysin. In: Tomasz A, editor. Streptococcus pneumoniae: molecular biology and mechanisms of disease. New York: Mary Ann Liebert, 2000: 279-86
17. Pericone CD, Overweg K, Hermans PWM, et al. Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun 2000; 68: 3990-7
18. Henriques-Normark B, Normark S. Commensal patho-gens, with a focus on Streptococcus pneumoniae, and in-teractions with the human host. Exp Cell Res 2010; 316: 1408-14
19. Learn DB, Brestel EP, Seetharama S. Hypochlorite scav-enging by Pseudomonas aeruginosa alginate. Infect Im-mun 1987; 55: 1813-8
20. Feldman C, Anderson R, Cockeran R, et al. The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro. Respir Med 2002; 96: 580-55
21. Marriott HM, Mitchell TJ, Dockrell DH. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med 2008; 8: 497-509
22. Feldman C, Munro N, Jeffery PF, et al. Pneumolysin in-duces the salient histologic features of pneumococcal infection in the rat lung in vivo. Am J Respir Cell Mol Biol 1991; 5: 416-23
23. Feldman C, Cockeran R, Jedrzejas MJ, et al. Hyaluroni-dase augments pneumolysin-mediated injury to human respiratory epithelium. Internat J Infect Dis 2007; 11: 11-5
24. Kadioglu A, Weiser JN, Paton JC, et al. The role of Streptococcus pneumoniae virulence factors in host colonization and disease. Nat Rev Microbiol 2008; 6: 288-301
25. Preston JA, Dockrell DH. Virulence factors in pneumo-coccal respiratory pathogenesis. Future Microbiol 2008; 3: 205-21
26. Sfrensen VB, Agger R, Bennedsen J, et al. Phosphoryl-choline determinants in six pneumococcal capsular poly-saccharides detected by monoclonal antibody. Infect Immun 1984; 43: 876-8
27. Ekdahl K, Braconier JH, Svanborg C. Impaired antibody response to pneumococcal capsular polysaccharides and phosphorylcholine in adult patients with a history of bacteremic pneumococcal infection. Clin Infect Dis 1997; 25: 654-60
28. Rajam G, Anderton JM, Carlone GM, et al. Pneumococcal surface adhesin A (PsaA): a review. Crit Rev Microbiol 2008; 34: 131-42
29. Mitchell AM, Mitchell TJ. Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect 2010; 16: 411-8
30. Papasergi S, Garibaldi M, Tuscano G, et al. Plasminogen-and fibronectin-binding protein B is involved in adherence of Streptococcus pneumoniae to human epithelial cells. J Biol Chem 2010; 285: 7517-24
31. Soong G, Muir A, Gomez MI, et al. Bacterial neur-aminidase facilitates mucosal infection by participating in biofilm production. J Clin Invest 2006; 116: 2297-305
32. Trappetti C, Kadioglu A, Carter M, et al. Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. J Infect Dis 2009; 199: 1497-505
33. Davis KM, Akinbi HT, Standish AJ, et al. Resistance to mucosal lysozyme compensates for the fitness deficit of peptidoglycan modifications by Streptococcus pneumo-niae. PLoS Pathog 2008; 4: e1000241
34. Lu L, Ma Z, Jokiranta TS, et al. Species specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol 2008; 181: 7138-46
35. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol 2009; 11: 1034-43
36. Stensballe LG, Hjuler T, Andersen A, et al. Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study. Clin Infect Dis 2008; 46: 1165-71
37. Grau I, Ardanuy C, Linares J, et al. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med 2009; 10: 488-95
38. Murdoch DR, Jennings LC. Association of respiratory virus activity and environmental factors with the incidence of invasive pneumococcal disease. J Infect 2009; 58: 37-46
39. Sun K, Metzger DW. Inhibition of pulmonary antibacter- ial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14: 558-64
40. Cockeran R, Durandt C, Feldman C, et al. Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils in vitro. J Infect Dis 2002; 186: 562-5
41. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-71
42. Ratner AJ, Hippe KR, Aguilar JL, et al. Epithelial cells are sensitive detectors of bacterial pore-forming toxins. J Biol Chem 2006; 281: 12994-8
43. Aguilar JL, Kulkarni R, Randis TM, et al. Phosphatase-dependent regulation of epithelial mitogen-activated protein kinase responses to toxin-induced membrane pores. PLoS One 2009; 4: e8076
44. Shin H-S, Yoo I-H, Kim Y-J, et al. MKP1 regulates the induction of MCP1 by Streptococcus pneumoniae pneumo-lysininhuman epithelial cells. Mol Cells 2010; 30(3): 263-70
45. Cockeran R, Theron AJ, Steel HC, et al. Proinflammatory interactions of pneumolysin with human neutrophils in vitro. J Infect Dis 2001; 183: 604-11
46. Cockeran R, Steel HC, Mitchell TJ, et al. Pneumolysin potentiates production of prostaglandin E(2) and leuko-triene B(4) by human neutrophils. Infect Immun 2001; 69: 3494-6
47. Witzenrath M, Gutbier B, Hocke AC, et al. Role of pneu-molysin for the development of acute lung injury in pneu-mococcal pneumonia. Crit Care Med 2006; 34: 1947-54
48. Garcia-Suarez M, del M, Florez N, Astudillo A, et al. The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model. Respir Res 2007; 8: 3
49. Mathias KA, Roche AM, Standish AJ, et al. Neutrophil-toxin interactions promote antigen delivery and mucosal clearance of Streptococcus pneumoniae. J Immunol 2008; 180: 6246-54
50. Dessing MC, Hirst RA, de Vos AF, et al. Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice. PLoS One 2009; 4: e7993
51. Opitz B, Puschel A, Schmeck B, et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 2004; 279: 36426-32
52. Ogunniyi AD, Grabowicz M, Briles DE, et al. Develop-ment of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007; 75: 350-7
53. Lu Y-J, Gross J, Bogaert D, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008; 4: e1000159
54. Zhang Q, Bagrade L, Bernatoniene J, et al. Low CD4 T cell immunity to pneumolysin is associated with nasophar-yngeal carriage of pneumococci in children. J Infect Dis 2007; 195: 1194-202
55. Malley R. Antibody and cell-mediated immunity to Strep-tococcus pneumoniae: implications for vaccine development. J Mol Med 2010; 88: 135-42
56. Klugman K, Madhi SA, Albrich WC. Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia. Clin Infect Dis 2008; 47: S202-6
57. Peters RPH, de Boer RF, Schuurman T, et al. Strepto-coccus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia. J Clin Microbiol 2009; 47: 3308-12
58. Smith MD, Sheppard CL, Hogan A, et al. Diagnosis of Streptococcus pneumoniae infections in adults with bac-teremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection. J Clin Microbiol 2009; 47: 1046-9
59. Abdeldaim G, Herrmann B, Molling P, et al. Usefulness of real-time PCR for lyt A, ply, and Spn802 on plasma samples for the diagnosis of pneumococcal pneumonia. Clin Microbiol Infect 2010; 16: 1135-41
60. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003; 41: 2810-3
61. Kruger S, Ewig S, Kunde J, et al. Assessment of inflam-matory markers in patients with community-acquired pneumonia-influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clinica Chimica Acta 2010; 411: 1929-34
62. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350: 451-8
63. Huh JW, Lim C-M, Koh Y, et al. Diagnostic utility of the soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage fluid from patients with bilateral lung infiltrates. Crit Care 2008; 12: R6
64. Muller B, Gencay MM, Gibot S, et al. Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumonia. Crit Care Med 2007; 35: 990-1
65. Jacobs MR. Antimicrobial-resistant Streptococcus pneu-moniae: trends and management. Expert Rev Anti Infect Ther 2008; 6 (5): 619-35
66. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010; 36: 197-204
67. Lynch III JP, Zhanel GG. Streptococcus pneumoniae: epi-demiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010; 16: 217-25
68. Linares J, Ardanuy C, Pallares R, et al. Changes in anti-microbial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010; 16: 402-10
69. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement M100-S18. Wayne (PA): CLSI, 2008
70. Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18 (4): 777-90
71. Metlay JP. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin Infect Dis 2002; 15: 163-7
72. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect 2002; 8 Suppl. 2: 1-11
73. Fuller JD, McGeer A, Low DE. Drug-resistant pneumo-coccal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis 2005; 24: 780-8
74. Yu VL, Chiou CCC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-7
75. Ho PL, Que TL, Ng TK, et al. Clinical outcomes of bac-teremic pneumococcal infections in an area with high resistance. Eur J Clin Microbiol Infect Dis 2006; 25: 323-7
76. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42: 224-33
77. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin Infect Dis 2006; 42: 234-7
78. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64
79. Lonks JR, Garau J, Medeiros AA. Implications of anti-microbial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002; 50 Suppl. S2: 87-91
80. Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 2002; 35: 565-9
81. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Manage-ment of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160 (10): 1399-408
82. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med 2004; 143 (5): 269-83
83. Klugman KP, Low DE, Metlay J, et al. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Int J Antimicrob Agents 2004; 24: 411-22
84. Aspa J, Rajas O, de Castro FR. Pneumococcal anti-microbial resistance: therapeutic strategy and manage-ment in community-acquired pneumonia. Expert Opin Pharmacother 2008; 9 (2): 229-41
85. Craig WA. Pharmacokinetic/pharmacodynamic parame-ters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
86. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-96
87. Andes D, Anon AD, Jacobs MR, et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004; 24 (2): 477-502
88. Smith HJ, Nichol KA, Hoban DJ, et al. Stretching the mutant prevention concentration (MPC) beyond its limits. J Antimicrob Chemother 2003; 51: 1323-5
89. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32 Suppl. 1: S39-46
90. Feldman C, Brink AJ, von Gottberg A, et al. Antimicrobial susceptibility of pneumococcal isolates causing bacter-aemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics. Int J Antimicrob Agents 2010; 36: 90-8
91. Houck PM, Bratzler DW. Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect outcomes? Curr Opin Infect Dis 2005; 18: 151-6
92. Berjohn CM, Fishman NO, Joffe MM, et al. Treatment and outcomes for patients with bacteremic pneumococcal pneumonia. Medicine 2008; 87 (3): 160-6
93. Gamacho-Montero J, Garcia-Cabrera E, Diaz-Martin A, et al. Determinants of outcome in patients with bacter-aemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis 2010; 42 (3): 185-92
94. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA 2000; 284 (13): 1670-6
95. Metersky ML, Sweeney TA, Getzow MB, et al. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours? Chest 2006; 130: 16-21
96. Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007; 131: 1205-15
97. Shorr AF, Owens Jr RC. Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid services. Am J Health-Syst Pharm 2009; 66 Suppl. 4: S2-7
98. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72
99. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneu-monia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107 Suppl. 1A: 34S-43S
100. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-42
101. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a b-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-95
102. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-4
103. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11 (8): 589-93
104. Harbarth S, Garbino J, Pugin J, et al. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005; 24: 688-90
105. Dwyer R, Ortqvist A, Aufwerber E, et al. Addition of a macrolide to a b-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 518-21
106. Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27: 1010-9
107. Chokshi R, Restrepo MI, Weeratunge N, et al. Mono- therapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2007; 26: 447-51
108. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33: 153-9
109. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combi-nation antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36: 612-20
110. Lode H, File Jr TM, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/ oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24 (11): 1915-36
111. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004; 3 (5): 329-36
112. Mortensen EM, Restrepo MI, Anzueto A, et al. The impact of empiric antimicrobial therapy with a b-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 2006; 10: R8
113. Feldman C, Anderson R. Therapy for pneumococcal bacteremia: monotherapy or combination therapy? Curr Opin Infect Dis 2009; 22: 137-42
114. FeldmanC,AndersonR.Non-antimicrobial activityofmacro-lides. Clin Drug Investig 2007;27 (Special Issue I):27-35
115. Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia: improved outcomes with macro-lides but not fluoroquinolones. Chest 2007; 131: 466-73
116. Calbo E, Alsina M, Rodriguez-Carballeira M, et al. The impact of time on the systemic inflammatory response in pneumococcal pneumonia. Eur Respir J 2010; 35: 614-8
117. Padrones S, Garcia-Vidal C, Fernandez-Serrano S, et al. Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. Eur J Clin Micro-biol Infect Dis 2010; 29 (10): 1243-51
118. Wise MP, Williams DW, Lewis MAO, et al. Macrolides and community-acquired pneumonia: is quorum sensing the key? Crit Care 2010; 14: 181
119. Marcos PJ, Waterer GW, Brienza NS, et al. Macrolides in community-acquired pneumonia: the importance of the non-antimicrobial effect. Curr Resp Med Rev 2010; 6: 150-4
120. McCabe C, Kirchner C, Zhang H, et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009; 169 (16): 1525-31
121. Fung HB, Monteagudo-Chu MO. Community-acquired pneumonia in the elderly. Am J Geriatr Pharmacother 2010; 8: 47-62
122. Ramirez JA. Switch therapy in adult patients with pneu-monia. Clin Pulm Med 1995; 2: 327-33
123. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155 (12): 1273-6
124. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54
125. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161: 848-50
126. Bordon J, Peyrani P, Brock GN, et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Chest 2008; 133: 618-24
127. Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722-7
128. Wunderink RG. Adjunctive therapyincommunity-acquired pneumonia. Semin Respir Crit Care Med 2009; 30: 146-53
129. Waterer GW, Rello J, Wunderink RG. Management of community-acquired pneumonia in adults. Am J Resp Crit Care Med. Epub 2010 Aug 6
130. Fukudu Y, Yanagihara K, Higashiyama Y, et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 2006; 27: 1020-5
131. Anderson R, Steel HC, Cockeran R, et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumo-niae. J Antimicrob Chemother 2007; 59: 224-9
132. Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 2007; 60: 1155-8
133. Ohara T, Kojio S, Taneike S, et al. Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 2002; 46: 3478-83
134. Nalca Y, Jansch L, Bredenbruch F, et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PA01: a global approach. Antimicrob Agents Chemother 2006; 50: 1680-8
135. Karlstrom A, Boyd KL, English BK, et al. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009; 199: 311-9
136. Feldman C, Anderson R, Theron A, et al. The effects of ke-tolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro. Eur Respir J 1999; 13: 1022-8
137. Feldman C, Anderson R. The cytoprotective interactions of antibiotics with human ciliated airway epithelium. In: Rubin B, Tamaoki J, editors. Antibiotics as anti-inflammatory and immunomodulatory agents. Basel: Birkhauser Verlag, 2005: 49-63
138. Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Che-mother 2002; 49: 745-55
139. Desaki M, Okazaki H, Sunazuka T, et al. Molecular mech-anisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signalling pathway that regulates nuclear factor-kappa B activation. Antimicrob Agents Chemother 2004; 48: 1581-5
140. Vanaudenaerde BM, Wuyts WA, Geudens N, et al. Macrolides inhibit IL-17-induced IL-8 and 8-isoprostane release from airway smooth muscle cells. Am J Transplant 2007; 7: 76-82
141. Weisfelt M, de Gans J, van der Poll T, et al. Pneumococcal meningitis in adults: new approaches to management and prevention. Lancet Neurol 2006; 5: 332-42
142. Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010; 9: CD004405
143. Confalonieri M, Urbino R, Potena A, et al. Hydro-cortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-8
144. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of sys-temic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30: 951-6
145. Snijders D, Daniels JMA, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia. Am J Respir Crit Care Med 2010; 181: 975-82
146. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-24
147. Barnes PJ. New molecular targets for treatment of neutrophilic diseases. J Allergy Clin Immunol 2007; 119: 1055-62
148. Niederman MS, Bass Jr JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26
149. Serezani CH, Ballinger MN, Aronoff DM, et al. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 2008; 39: 127-32
150. Tintinger GR, Steel HC, Theron AJ, et al. Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorpho-nuclear leukocytes. Drug Des Devel Ther 2009; 2: 95-104
151. Parry GCN, Mackman N. Role of cyclic AMP response element binding protein in cyclic AMP inhibition of NF-κB-mediated transcription. J Immunol 1997; 159: 5450-6
152. Anderson R, Goolam Mahomed A, Theron AJ, et al. Effects of rolipram and dibutyryl cyclic AMP on re-sequestration of cytosolic calcium in FMLP-activated human neutrophils. Br J Pharmacol 1998; 124: 547-55
153. Anderson R, Theron AJ, Gravett CM, et al. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol 2009; 156: 105-15
154. Gravett CM, Theron AJ, Steel HC, et al. Interactive in-hibitory effects of formoterol and montelukast on activated human neutrophils. Eur Respir J 2010; 36 (6): 1417-24
155. Bernardin G, Strosberg AD, Bernard A, et al. Beta-adre-nergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med 1998; 24: 1315-22
156. Silverman HJ, Penaranda R, Orens JB, et al. Impaired b-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993; 21: 31-9
157. Ognibene FP, Cunnion RE. Mechanisms of myocardial depression in sepsis. Crit Care Med 1993; 21: 6-8
158. Adel M, Awad HA, Abnel-Naim AB, et al. Effects of pentoxifylline on disseminated intravascular coagulation incidence in Egyptian septic neonates. J Clin Pharm Ther 2010; 35: 257-65
159. Harris E, Schulzke SM, Patole SK. Pentoxifylline in pre-term neonates: a systematic review. Paediatr Drugs 2010; 12: 301-11
160. Tarnow-Mordi W, Isaacs D, Dutta S. Adjunctive im-munologic interventions in neonatal sepsis. Clin Perinatol 2010; 37: 481-99
161. Ledeboer A, Hutchinson MR, Watkins LR, et al. Ibudilast (AV-411) a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007; 16: 935-50
162. Garcia-Suarez M del M, Cima-Cabal MD, Florez N, et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 2004; 72: 4534-40